$PEN News

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy

Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $320

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Penumbra’s Thunderbolt approval poised to accelerate neuro thrombectomy innovation

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

Penumbra's Thunderbolt Device Offers Revenue Upside Not Reflected in Estimates, RBC Says

RBC Capital Reiterates Sector Perform on Penumbra, Maintains $374 Price Target

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

Penumbra's THUNDERBOLT Gets FDA Clearance To Treat Acute Ischemic Stroke

GMED or PEN: Which Is the Better Value Stock Right Now?

Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion

Penumbra Inc (NYSE:PEN) Shows Strong Growth and Bullish Technical Setup

Citigroup Maintains Neutral on Penumbra, Lowers Price Target to $350